雷利度胺联合化疗治疗急性白血病的临床效果及对血管生成因子的影响

Clinical Curative Efficacy of Lenalidomide Combined with Chemotherapy for Acute Leukemia and Its Impact on VEGF

目的:探讨雷利度胺联合化疗治疗急性白血病的临床疗效和对VEGF、bFGF表达的影响,分析雷利度胺与白血病疗效的关系。方法:对2013年10月至2014年10月期间我院收治的初发急性髓系白血病(M3除外)患者,随机分为化疗+安慰剂组、雷利度胺+化疗组及健康组。检测临床疗效和VEGF及 FGF的表达。结果:雷利度胺+化疗组与化疗+安慰剂组有效率分别为87.9%和77.2%。治疗前雷利度胺+化疗组和化疗+安慰剂组血浆VEGF水平远高于健康组,治疗后血浆VEGF水平明显下降,且在雷利度胺+化疗组下降幅度大于化疗+安慰剂组。同样治疗前雷利度胺+化疗组和化疗+安慰剂组血浆bFGF水平高于健康组,治疗后血浆bFGF水平明显下降,且在雷利度胺+化疗组下降幅度大于化疗+安慰剂组。结论:雷利度胺联合化疗使血管新生因子VEGF及bFGF表达明显下降,并提高急性白血病缓解率。

Objective: To investigate the clinical efficacy of regimen consisting of lenalidomide combined w ith chemotherapy for acute leukemia and its impact on vascular endothilial grow th factor( vEGF) and basic fibroblast grow th factor( b FGF),and to analyze the relationship lenalidomide w ith therapeutic efficacy of leukemia. Methods: The patients w ith new ly diagnosed acute myeloid leukemia( except M3) from October 2013 to October 2014 in our hospital w ere randomly divided into 2 groups: chemotherapy + placebo( CP) group and lenalidomide + chemotherapy( LC)group. In addition,healthy persons w ere used as healthy controls( HC). The expression of VEGF and b FGF w as detected by ELISA,and the therapeutic efficacy for AML patients w as analyzed. Results: The therapeutic efficacy in LC group and CP group w as 87. 9% and 77. 2% respectively. Before treatment,the VEGF level in LC and CP groups w as obviously higher than that in HC group; after treatment,the VEGF level significanthy decreased,and the decreased degree in LC group w as larger than that in CP group. Before treatment,the b FGF level in LC and CP groups w as higher than that in HC group; after treatment,the b FGF level decreased,and decreased degree in LC group w as larger than that in CP group. Conclusion: The lenalidomide combined w ith chemotherapy can significantly decrease the expression level of VEGF and b FGF,and enhance the remission rate of patients w ith AML.